Antibodies targeting aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) define disease processes that can cause immune-mediated spinal cord dysfunction and have clinical features, treatment considerations and prognoses distinct from multiple sclerosis (MS) (1–17). Here, AQP4 is linked to myeloid sarcoma.